**This article has been corrected:** In this para, the term "somatic mutation" should be replaced with "genetic mutation" is given below:

The *SEL1L* gene spans more than 62.24 kb pairs within a "gene desert region" and displays only weak linkage disequilibrium pattern according to the HapMap CEU population data. A total of five single nucleotide genetic variants in the *SEL1L* gene (GenBank Reference sequence NM_005065) were selected (Table 6). Two of them (c.--366T \> C and c.--354T \> C) were first identified in the minimal promoter region of the *SEL1L* gene in lung carcinoma patients \[47\]. The c.341--88T \> C genetic variant is a common SNP (rs12435998) within intron 3, containing potential binding sites for transcription factors involved in ER-induced stress, and it is a predicted splice site \[23\]. The c.485A \> G (p.Asp162Gly) variant corresponds to the SNP rs11499034, maps in exon 4 encoding for the fibronectin type II domain (FN2), and affects a highly conserved amino acid residue \[24\]. The amino acid change from Asp to Gly may have a disruptive role in the collagen binding. The c.1972T \> C (p.Ser658Pro) variant in exon 19 has been described as genetic mutation responsible for the progressive early-onset cerebellar ataxia in canine species \[49\]. Of note, the *SEL1L* gene is highly conserved between dog and human, with 98% identity at protein level (HomoloGene). The Ser658 residue located in the eleventh *SEL1L*-like repeat is completely conserved in all aligned vertebrates and maps within a functionally relevant domain for tumor growth inhibition \[50\].
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